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Abstract: 
Objective: Diabetes Mellitus contributes to excessive cardiovascular deaths and reduced life 
expectancy in schizophrenia. This population-based cohort study investigated the endogenous 
risk for DM in antipsychotic-naive schizophrenia, and evaluated the risks, added by starting 
antipsychotics in people with schizophrenia.  
Method: We followed all people, born in Denmark on or after 01/01/1977 until 01/01/2013 
(N=2,736,510). The Danish Psychiatric Central Research Register ascertained schizophrenia 
diagnoses. The Danish National Prescription Registry provided data on prescriptions of 
antipsychotics. Diabetes was ascertained from the Danish National Patient Register and Danish 
National Prescription Registry. We estimated the endogenous and antipsychotic-related risks for 
diabetes using Cox proportional hazards regression models, while accounting for potential 
confounders.  
Results: 14,118 (0.52%) developed diabetes, and 8,945 (0.33%) developed schizophrenia during 
follow-up (49,582,279 person-years). Adjusted hazard ratio for diabetes was 3.07 (95% CI 1.71-
5.41) in antipsychotic-naive schizophrenia compared with the general population. Risk for 
diabetes after starting antipsychotics was significantly higher (Adjusted hazard ratio =3.64; 95% 
CI 1.95-6.82) than the risk in antipsychotic-naive schizophrenia, after adjusting for family 
history of diabetes and other potential confounders. First-line treatment with either first-
generation antipsychotics (Adjusted hazard ratio =3.06; 95% CI 1.32-7.05) or second generation 
antipsychotics (Adjusted hazard ratio=3.44; 95% CI 1.73-6.83) increased risks for diabetes 
without statistically significant difference (χ
2
=0.13; p=0.72). Appropriate sensitivity analyses, 
limited to type-2 diabetes, corroborated these results. 
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Conclusions: Schizophrenia confers high endogenous risk for diabetes, and the risks are further 
increased by both first-generation and second-generation antipsychotics. Early detection and 
effective treatment of diabetes should be an integral part of multidisciplinary management of 
schizophrenia regardless of antipsychotic drug exposure. 
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Introduction:  
 Prevalence of Diabetes Mellitus is four to five times higher among people with 
schizophrenia than the general population (1). Those, who suffer from both diabetes and 
schizophrenia, have 3-4 fold higher overall mortality rates than general population, and at least 
one-third of those deaths can be attributed to diabetes (2). Diabetes contributes to excessive 
cardiovascular deaths and more than 20 years of reduced life expectancy in people with 
schizophrenia (3,4). Young people with schizophrenia, aged less than 40 years, are at high risk 
(5) for early-onset type-2 diabetes that is a rapidly progressing severe disease subtype with 
increased risks for microvascular and macrovascular complications (4,6-8).  
Studies from the pre-neuroleptic era (9) have reported increased prevalence of diabetes, 
impaired glucose tolerance, and increased insulin resistance in people with schizophrenia (10-
12). Abnormal glucose tolerance is more prevalent in antipsychotic naïve people with 
schizophrenia than among healthy controls, and this association is independent of the effects of 
Body Mass Index and of poor health habits (13-15). Moreover, increased prevalence of diabetes 
among the first-degree relatives of people with schizophrenia indicates a potential genetic link 
between schizophrenia and diabetes (16,17). TCF7L2 and IGF2BP2, two of the most replicated 
susceptibility genes for type-2 diabetes, have been associated with schizophrenia (18-20). 
Furthermore, linkage studies, genetic association studies, and pathway analyses have supported 
shared genetic risks between these two disorders (21-23).  
As soon as chlorpromazine was introduced in 1952, there were several reports of its 
association with diabetes and impaired glucose tolerance (10). After the introduction of second-
generation antipsychotic drugs, their association with diabetes has been investigated more 
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systematically (24-28). A meta-analysis, not including data on aripiprazole, ziprasidone, and 
amisulpride, has concluded that second-generation antipsychotics confer more risk for diabetes 
in schizophrenia than first-generation antipsychotic drugs (29). However, a longitudinal study 
has reported that both second-generation antipsychotics and first-generation antipsychotics 
increase the risk for diabetes, and that second-generation antipsychotics, as a class, confer 
significantly less risk for incident diabetes than first-generation antipsychotics (30). Individual 
first-generation and second-generation antipsychotics may differ widely on their risks for 
diabetes (30-32). Clozapine may confer higher risk for diabetes than other second-generation 
antipsychotics (31,33). A recent meta-analysis has reported the incidence of type-2 diabetes in 2-
24 year olds, exposed to antipsychotics, as 3.09 (95% CI, 2.35-3.82) per 1000 person-years, and 
it has added that the risk for early-onset type-2 diabetes was significantly higher in those, who 
received second-generation antipsychotics prescriptions (34). Dose-response effects (30) and 
several plausible biological mechanisms (21) indicate a causal association between 
antipsychotics and diabetes. Antagonism of central and peripheral M3, H1, 5HT2c, other 
serotonergic, and of adrenergic receptors may have direct diabetogenic effects, or can increase 
the risk of diabetes by indirect mechanisms, such as weight-gain, and reduced insulin sensitivity 
(21,31,35).  
There are several caveats in our current understanding of endogenous and antipsychotic-
related risks of diabetes in schizophrenia. Firstly, there has not been any large population-based 
cohort study investigating endogenous risk for diabetes in antipsychotic naïve people with 
schizophrenia compared with the general population. Secondly, population-based cohort studies 
focusing on the risks for early-onset diabetes in young people with schizophrenia are sparse (34). 
Thirdly, despite a large volume of literature, impact of the first-line therapeutic decision of 
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choosing between first-generation and second-generation antipsychotics on the antipsychotic-
related risk for diabetes in schizophrenia remains uncertain (29,30). Fourthly, previous studies 
investigating the antipsychotic-related risks for diabetes in schizophrenia have seldom been 
adjusted for the effects of family history of diabetes and for the dosage of other potentially 
diabetogenic psychotropic medications (36-38). Hence, this population-based cohort study 
included all young people (more than 2.7 million), born on 01/01/1977 or later in Denmark, 
investigated endogenous risk for early-onset diabetes in antipsychotic naïve schizophrenia, and 
evaluated the antipsychotic-related risks in people with schizophrenia, after adjusting for the 
effects of potential confounders.  
Method: 
Study population: This population-based cohort study included people from the Danish Civil 
Registration System (39), recording data of all Danish citizens since 1968. Each Danish citizen is 
assigned a unique 10-digit personal identification number at birth. This number is used in all 
Danish registries enabling unambiguous linkage among them. Danish Civil Registration System 
provides data on gender, date of birth, date of death, date of migration, and parental identity. Our 
cohort included all people that were born in Denmark on or after 01/01/1977. They were 
followed up until 01/01/2013.  
People with diabetes: Information on diabetes was derived from the Danish National Patient 
Register (40), and the Danish National Prescription Registry (41). Danish National Patient 
Register, established in 1977, collects data on all hospitalisations from non-psychiatric hospitals, 
including dates of admission and discharge, and discharge diagnoses, coded by the treating 
physicians according to the International Classification of Diseases (ICD) (8
th
 revision (ICD-8) 
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(42) until the end of 1993, and 10
th
 revision (ICD-10) (43) thereafter). Since 1995, outpatient 
visits have also been recorded. We identified all hospital discharge diagnoses of diabetes (ICD-8: 
249 (insulin-dependent diabetes (type-1)) and 250 (non-insulin-dependent diabetes (type-2)); and 
ICD-10: E10 (brittle, juvenile, and ketoacidosis prone diabetes), E11 (adult-onset, maturity-
onset, nonketotic, and stable diabetes), E12-14 (malnutrition, other specified and unspecified 
diabetes), H36.0 (diabetic retinopathy), O24 (diabetes in pregnancy, childbirth and puerperium 
excluding O24.4 (gestational diabetes)). Both the ICD-8 and ICD-10 do not provide specific 
codes for late-onset type-1 diabetes in adults or drug-induced diabetes. As people with 
schizophrenia may develop type-2 diabetes at younger ages than the general population, as well 
as coding practice of diabetes in the Danish registers indicating more frequent use of unspecified 
diabetes codes in people with schizophrenia, we examined the complete spectrum of ICD 
diabetes codes. Although using Danish National Patient Register and Danish National 
Prescription Registry to identify people with diabetes has proven to be of high quality and almost 
complete (44,45), we cannot reliably distinguish type-1 and type-2 diabetes using the registers 
(46,47). 
 In addition to hospital contacts with diabetes, we identified antidiabetic prescriptions 
from the Danish National Prescription Registry, because many people with diabetes are treated 
only in primary care. The Danish National Prescription Registry contains data from 1995 on all 
prescription drugs, dispensed at all Danish pharmacies, including their Anatomical Therapeutic 
Chemical (ATC) classification system codes, dispensing dates, drug names, dose units, number 
of dose units in package, number of sold Daily Defined Doses (DDD) (48), and dispensing 
pharmacy codes. Antidiabetic drugs are only available by prescription in Denmark, so we 
identified all prescription redemptions for antidiabetic drugs (ATC-codes: A10). However, 
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women with polycystic ovary syndrome may be treated with metformin (ATC-code: A10BA02). 
Thus, to avoid inclusion of these nondiabetic people, we excluded all metformin-prescriptions, 
redeemed by women aged 20 or more years in this cohort. Onset of diabetes was defined as the 
date of first admission with diabetes since birth or as the date of the first prescription for an 
antidiabetic drug since 1995 or later, whatever came first.  
People with schizophrenia: Danish Psychiatric Central Research Register (DPCRR) (49) was 
established as an electronic database in 1969, and has been recording data on all psychiatric 
admissions since 1969. Diagnoses in DPCRR are coded in accordance with the ICD-8 (42) until 
the end of 1993, and ICD-10 (43) thereafter. DPCRR includes data on all out-patient visits since 
1995. We identified all hospital discharge diagnoses of schizophrenia (ICD-8: 295 (excluding 
295.79) and ICD-10: F20). These diagnoses have been validated (50), and have contributed 
substantially to epidemiological research (49). As Danish National Prescription Registry data has 
been complete only since 1995, we excluded all people (n=97), who developed schizophrenia 
before 01/01/1996, to ensure that we had complete psychopharmacological data and at least one 
year prescription use history of all people with schizophrenia after they had been diagnosed. 
Hence, we included all incident schizophrenia cases since 01/01/1996. 
Exposure to antipsychotics: We traced all oral and depot antipsychotic prescriptions (ATC-
codes: N05A, excluding N05AN: lithium) since 1995 using information from the Danish 
National Prescription Registry (48). The Danish National Prescription Registry is a powerful 
pharmacoepidemiological tool that provides complete high quality data of all filled prescriptions 
of antipsychotics, prescribed by various psychiatric departments, general practitioners, or other 
specialists, after 1995. It does not record the drugs that are dispensed within hospitals. All 
Danish pharmacies are obliged to register all dispensed prescriptions, and they have a high 
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economic incentive for completeness of prescription registration, because of the universal 
reimbursement system of prescription drugs in Denmark. Antipsychotics were subdivided into 
first-generation antipsychotics, second-generation antipsychotics (ATC-codes: N05AD03, 
N05AE03-4, N05AH04, N05AL01, N05AL05, N05AX08, and N05AX13), olanzapine, 
aripiprazole, and clozapine (See eAppendix-1 in the supplemental data). 
Covariates of interest: We chose our covariates a priori on the basis of their availability, 
previous research associating them with diabetes or schizophrenia, and their influence on the 
prescribing pattern of antipsychotics. From the Danish National Prescription Registry, we 
identified other potentially diabetogenic psychotropic medications, such as tricyclic (ATC-codes: 
N06AA) and tetracyclic (ATC-codes: N06AA21, N06AX03, N06AX11) antidepressants (36), 
and valproate (ATC- code: N03AG01) (37,38). Data on gender, urbanicity, and calendar period 
were derived from Danish Civil Registration System and Danish National Patient Register (40). 
Using the parental identity from Danish Civil Registration System, we identified siblings and 
half-siblings, and linked them to Danish National Patient Register and Danish National 
Prescription Registry to establish family history of diabetes. 
Statistical analyses: We calculated age-specific and gender-specific incidence rates of diabetes 
and their 95% confidence intervals (95% CI). In order to investigate the endogenous risk for 
diabetes, we used Cox proportional hazards regression models to compute adjusted hazard ratio 
for diabetes in antipsychotic naïve people with schizophrenia, compared with antipsychotic naïve 
people without schizophrenia. Follow-up began on the date of birth and ended on the date of 
diabetes diagnosis, first prescription of antipsychotics, emigration, death, or on 01/01/2013. The 
first registered diagnosis of schizophrenia during follow-up was included as a time-dependent 
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variable. Gender, family history of diabetes, urbanicity, and exposure to valproate and tricyclic 
or tetracyclic antidepressants were included as covariates.  
 We assessed antipsychotic-related risk for diabetes by including only people with 
schizophrenia, who were antipsychotic naive at the time of their diagnosis. We employed Cox 
proportional hazards regression models estimating adjusted hazard ratio by comparing the rates 
of diabetes in people with schizophrenia with and without antipsychotics. Follow-up began on 
the date of first diagnosis of schizophrenia, and ended on the date of diabetes diagnosis, 
emigration, death, or on 01/01/2013. Age was chosen as the time scale. Our Cox regression 
model included gender, family history of diabetes, and urbanicity as time-independent 
covariates, and calendar period, DDD of antipsychotics, DDD of valproate, and DDD of tricyclic 
or tetracyclic antidepressants as time-varying covariates. Moreover, we estimated Adjusted 
hazard ratio and their 95% CI comparing the risks for diabetes before and after starting selected 
antipsychotics in people with schizophrenia. Furthermore, we performed sensitivity analyses 
following the people until their first type-2 diabetes contact (ICD-8: 250, ICD-10: E11, O24.1, 
and/or oral antidiabetic drug (ATC-codes: A10B) ignoring any previous contacts due to type-1 
diabetes or insulin prescriptions. We tested the proportional hazards assumption by repeating the 
Cox regression models including the primary independent variable as one of the time-varying 
covariates, and we did not find any violations. All analyses were performed using the statistical 
software STATA 13.1 (StataCorp, Texas, USA).  
Results: 
Population Characteristics: We followed 2,736,510 young people for a total of 49,582,279 
person-years. Median duration of follow-up was 18.80 (IQR=16.99) years. Maximum period of 
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follow-up was 35.96 years, thus the oldest in our cohort was less than 36 years old. A total of 
8,945 (0.33%) people developed schizophrenia during follow-up. Mean duration of follow-up 
after the diagnosis of schizophrenia was 5.07 (SD=4.24) years, and mean duration of follow-up 
after the first antipsychotic drug prescription was 6.40 (SD=4.34) years. Table 1 presents the 
sociodemographic, and clinical characteristics of our cohort. People with schizophrenia were 
significantly more likely to have family history of diabetes than other people (χ
2
>1300; 
p<0.001).  
Incidence of diabetes: A total of 14,118 (0.52%) people developed diabetes in this cohort (See 
eFigure1 in the supplemental data). Age-specific incidence rates of diabetes in people with and 
without schizophrenia are presented in Table 2 (See eFigure 2 in the supplemental data). Gender-
specific incidence rates of diabetes for men and women without schizophrenia were 0.26 (95% 
CI 0.26-0.27), and 0.30 (95% CI 0.29-0.31) per 1000 person-years, respectively. Gender-specific 
incidence rates of diabetes for men and women with schizophrenia were 4.02 (95% CI 3.35-
4.83), and 4.69 (95% CI 3.81-5.77) per 1000 person-years, respectively.  
Endogenous risk for diabetes: Among the people, who have not been exposed to any 
antipsychotics, 12,976 (0.5%) without schizophrenia, and 11 (0.9%) with schizophrenia 
developed incident diabetes during our follow-up. Table 3 presents the incidence rates and the 
Adjusted hazard ratio for diabetes in antipsychotic naïve people with schizophrenia. Family 
history of diabetes significantly increased the risk of diabetes (Adjusted hazard ratio=3.96; 95% 
CI 3.82-4.11). People with schizophrenia had higher incidence rates of diabetes, and they had 
approximately three-fold higher rates (Adjusted hazard ratio=3.07; 95% CI 1.71-5.41) of 
diabetes, compared with people without schizophrenia, after adjusting for the effects of potential 
confounders including family history of diabetes. 
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Antipsychotic-related risks: A total of 4,322 (48.3%) people with schizophrenia were 
antipsychotic naïve at the time of their diagnosis, and the remaining 4,623 (51.7%) had received 
an antipsychotic drug, before schizophrenia was diagnosed. A total of 83 (1.9%) people with 
schizophrenia, who were antipsychotic naïve at diagnosis, developed diabetes during follow-up. 
Gender-specific incidence rates of diabetes for antipsychotics treated men and women with 
schizophrenia, were 4.22 (95% CI 3.17-5.62), and 3.33 (95% CI 2.23-4.96) per 1000 person-
years, respectively. Table 4 presents the incidence rates and the Adjusted hazard ratio for 
diabetes in people with schizophrenia comparing their risks before and after starting selected 
antipsychotics. Rates for diabetes significantly increased by more than three-fold (Adjusted 
hazard ratio=3.64; 95% CI 1.95-6.82) in people with schizophrenia after starting any 
antipsychotic, compared with their rates before receiving antipsychotics, while accounting for 
the effects of potential confounders including family history of diabetes. 
First-line treatment with first-generation or second-generation antipsychotics: Compared to 
the people with schizophrenia, who remained antipsychotic naive until the end of follow-up, 
those with schizophrenia, who received either first-generation (Adjusted hazard ratio=3.06; 95% 
CI 1.32-7.05) or second-generation antipsychotics monotherapy (except clozapine) (Adjusted 
hazard ratio=3.44; 95% CI 1.73-6.83) as their first-line treatment, had significantly higher 
antipsychotic-related rates for diabetes after adjusting for the effects of potential confounders 
including family history of diabetes. The first-line therapeutic decision of choosing between 
first-generation and second-generation antipsychotics did not make statistically significant 
difference (χ
2
=0.13; p=0.72) on the rates for diabetes in people with schizophrenia. We repeated 
these analyses after excluding olanzapine from the class of second-generation antipsychotics and 
confirmed earlier findings.  
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Risks associated with selected antipsychotics: Starting either olanzapine (Adjusted hazard 
ratio=1.88; 95% CI 1.36-2.59) or aripiprazole (Adjusted hazard ratio=2.35; 95% CI 1.70-3.26) 
significantly increased the rates of diabetes by almost two-fold in people with schizophrenia, 
after adjusting for the effects of potential confounders. We repeated these analyses including the 
duration of antipsychotic treatment before starting either olanzapine (Adjusted hazard ratio=1.91; 
95% CI 1.37-2.65) or aripiprazole (Adjusted hazard ratio=1.69; 95% CI 1.19-2.39) in the 
models, and confirmed earlier findings. Among 861 (9.6%) people with schizophrenia, who 
received clozapine after their diagnosis, 39 (0.4%) developed incident diabetes after starting 
clozapine. Treatment with clozapine significantly increased the rate of diabetes by nearly four-
fold (Adjusted hazard ratio=3.98; 95% CI 2.77-5.73) in people with schizophrenia, compared 
with people with schizophrenia not receiving clozapine, after accounting for the potential 
confounders including the family history of diabetes (See eAppendix 2 in the supplemental data). 
Sensitivity analyses: We conducted sensitivity analyses, limited to potential type-2 diabetes 
diagnoses in this cohort (n=5,488; 0.20%), and confirmed earlier findings of higher rates of 
diabetes in antipsychotic naive schizophrenia compared with the general population (Adjusted 
hazard ratio=4.71; 95% CI 2.60-8.51), and increased rate of diabetes after starting any 
antipsychotic drug in people with schizophrenia (Adjusted hazard ratio=3.79; 95% CI 1.97-7.26) 
without statistically significant differences between first-generation and second-generation 
antipsychotics (χ
2
=0.04; p=0.85) (See eAppendix-2,3,5 in the supplemental data). We performed 
more sensitivity analyses after excluding 19 people, who developed diabetes more than 12 
months after the last prescription of any antipsychotic, to distinguish direct antipsychotic effects 
from the potential effects of antipsychotic-related weight-gain. Results of this sensitivity analysis 
also corroborated our earlier findings. Antipsychotic-related risk for diabetes after starting any 
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antipsychotic was significantly higher (Adjusted hazard ratio=3.28; 95% CI 1.74-6.17) than the 
risk in people with schizophrenia, not treated with antipsychotics, and the first-line therapeutic 
decision of treatment with either first-generation or second-generation antipsychotics 
monotherapy did not make statistically significant difference (χ
2
=0.78; p=0.38). Moreover, we 
performed sensitivity analyses by including women, aged 20 or more years, receiving treatment 
only with metformin (n=8,551). We confirmed our findings of endogenous risk of diabetes in 
antipsychotic naive schizophrenia (Adjusted hazard ratio=2.10; 95% CI 1.30-3.38), and 
increased rate of diabetes after starting any antipsychotic drug in people with schizophrenia 
(Adjusted hazard ratio=3.56; 95% CI 2.09-6.06) without statistically significant difference 
(χ
2
=2.03; p=0.15) between the first-line therapeutic decision of treatment with either first-
generation antipsychotics (Adjusted hazard ratio=4.27; 95% CI 2.21-8.27) or second-generation 
antipsychotics (Adjusted hazard ratio=2.98; 95% CI 1.67-5.32) monotherapy. 
Discussion: 
 This nation-wide population-based cohort study has revealed an increased endogenous 
risk for diabetes in antipsychotic naïve people with schizophrenia compared with people without 
schizophrenia. It has confirmed the antipsychotic-related risks for diabetes in people with 
schizophrenia after adjusting for potential confounders including family history of diabetes. 
Moreover, it has added evidence that first-line treatments with either first-generation or second-
generation antipsychotics do not significantly differ on their antipsychotic-related risks for 
diabetes. Furthermore, it has documented that the antipsychotic-related rates of diabetes in 
people with schizophrenia, who had received other antipsychotics, further increased four-fold 
after starting clozapine. Strengths of this study include the hitherto largest sample size, the 
hitherto longest follow-up, studying antipsychotic naive people with schizophrenia, focus on 
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early-onset diabetes in young people, and statistical adjustments for the effects of family history 
of diabetes and other potentially diabetogenic medications. 
 An important limitation of our study is that we could not reliably distinguish between 
type-1 and type-2 diabetes. Misclassification between type-1 and type-2 diabetes is likely, and a 
complete classification is not possible on the basis of the information available in Danish 
national registers (47,51). We can only distinguish between type-1 and type-2 diabetes on the 
basis of ICD codes and insulin-only therapy potentially indicating type-1 diabetes. Moreover, 
people with schizophrenia are often diagnosed with ICD-10 codes for unspecified diabetes. 
However, sensitivity analyses, limited to potential type-2 diabetes, corroborated our findings. A 
substantial proportion of incident diabetes in young people with schizophrenia is expected to be 
early-onset type-2 diabetes (52). Early-onset type-2 diabetes can be a distinct severe rapidly 
progressing disease phenotype (4,7,8). This may limit generalisability of our findings to older 
people with schizophrenia, but may emphasise their clinical importance. Besides, the possibility 
of increased surveillance of people with schizophrenia by the health services, and consequent 
surveillance bias may explain the increased incidence of diabetes in antipsychotic-naive 
schizophrenia. However, prior evidence suggests that the proportion of undiagnosed diabetes 
may be higher among people with schizophrenia than the general population (53,54). Moreover, 
studying a relatively homogenous and predominantly Caucasian population from a single 
country may limit generalisability of our findings, but this should strengthen their internal 
validity (55). Other limitations of this study include lack of data on other potential confounders, 
such as obesity, dyslipidaemia, smoking, other substance abuse, diet, and sedentary life style, 
lack of data on drugs dispensed within hospitals in Danish National Prescription Registry, and 
grouping diverse antipsychotics together during our analyses. Controlling for all potential 
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confounders is not possible in register-based research (56), and such residual confounding could 
have influenced our results. 
 High prevalence of endogenous diabetes in antipsychotic naïve people with schizophrenia 
has been reported in a different Danish cohort (31,33), and our findings have confirmed higher 
incidence of endogenous diabetes in young people with schizophrenia. In our study, young 
people with schizophrenia were significantly more likely to have family history of diabetes. This 
finding indicates familial aggregation and genetic overlap of these two disorders. A recent 
population-based cross-sectional study from Australia has reported that people with psychosis 
are at increased risk of diabetes if they have family history of diabetes or if they do not have 
family history of diabetes but are taking antipsychotics (57). Our results, adjusted for the family 
history of diabetes, have clarified this misconception, and have established that people with 
schizophrenia are at increased risk for diabetes regardless of their family history of diabetes, and 
of antipsychotic drug exposure.  
 Previous studies have reported that second-generation antipsychotics as a class conferred 
more risks for diabetes than first-generation antipsychotics (29). However, evidence to the 
contrary also exists (30). Our findings have added important evidence to this debate. Similarly, 
aripiprazole has been reported either lowering (31) or increasing (58) the risk for diabetes in 
schizophrenia. Our findings did not support the protective effect of aripiprazole, but documented 
its risk for diabetes. There is a possibility that aripiprazole and first-generation antipsychotics 
might have been prescribed more often for diabetes-prone people with schizophrenia, and such 
channelling bias might have influenced pertinent findings. Similarly, olanzapine might have been 
prescribed more often for people, perceived to be less prone for diabetes, by their treating 
clinicians, and this could have underestimated the associated risks. Considering the diabetogenic 
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potential of olanzapine, a three-phased algorithm for antipsychotic treatment limiting use of 
olanzapine only as a second-line antipsychotic agent has been proposed (33). First-line treatment 
with second-generation antipsychotics including olanzapine did not differ significantly from 
first-generation antipsychotics on their risks for diabetes in this cohort. Olanzapine has not been 
a second-line antipsychotic in many countries including Denmark at the time of this cohort, and 
it is currently recommended as a first-line antipsychotic for schizophrenia by many national (59) 
and international (60) guidelines. Our findings have not added evidence to change the prevailing 
guidelines regarding prescription of olanzapine in schizophrenia. However, they confirmed the 
substantial increase in the risks for diabetes by starting clozapine in people with schizophrenia. 
 Shared genetic factors, negative symptoms, substance abuse, and unhealthy lifestyle in 
schizophrenia may contribute to its endogenous risk for diabetes. Future studies should focus on 
underlying biological mechanisms connecting these two disorders, and on potential preventive 
interventions. Further studies investigating antipsychotic-related risks of individual 
antipsychotics and of their polypharmacy (30,61) for diabetes in people with schizophrenia are 
warranted. Antipsychotic-related risk for diabetes is often discussed as one of the many factors 
during the therapeutic decision making process of choosing an antipsychotic agent in psychiatric 
clinics. Combined endogenous and antipsychotic-related risks for diabetes in schizophrenia 
mandate more attention. Psychiatric services should either develop specific protocols or closely 
collaborate with primary care facilities to screen for diabetes among people with schizophrenia 
in community. Promoting healthy life style, early detection by regular, at least yearly, screening 
and effective treatment of diabetes should be an integral part of multidisciplinary management of 
schizophrenia.  
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Table 1: Sociodemographic and clinical profile of people with (n=8,945) and without 
(n=2,727,565) schizophrenia 
Characteristic Without 
schizophrenia 
With schizophrenia 
 n  % n  % 
Gender  
           Men 1,384,625 50.8 5,342 59.7 
          Women 1,342,940 49.2 3,603  40.3 
Urbanicity  
          Copenhagen 
a 
553,452 20.3 2,176 24.3 
          Other cities 
b 
254,497 9.3 944 10.6 
          Towns 
c 
678,502 24.9 2,506 28.0 
          Rural areas
 
1,241,114 45.5 3,319 37.1 
Family history of Diabetes  202,500 7.4 1,537 17.2 
Incident Diabetes Mellitus 13,915  0.5 203 2.3 
Exposure to antipsychotics   
          First-generation antipsychotics  34,691 1.3 5,050 56.5 
          Second-generation antipsychotics 
d 
26,887 1.0 6,291 70.3 
          Olanzapine 7,475 0.3 3,613 40.4 
          Aripiprazole 5,479 0.2 3,511 39.3 
          Clozapine 65 0.002 912 10.2 
Being antipsychotic naïve 
e 
2,673,114 98.0 1,154  12.9 
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Exposure to antidepressants 
f 
51,803 1.9 2,296  25.7 
Exposure to valproate 12,757 0.5 524 5.9 
 
a 
Living in the capital city, Copenhagen, and its suburbs; 
b
 Living in other cities with more than 
100,000 population; 
c
 Living in towns with population between 10,000 and 100,000; 
d
 Second 
Generation Antipsychotic drugs excluding olanzapine, aripiprazole, and clozapine; 
e
 People, who 
have not received any antipsychotic medications until the end of their follow-up; 
f 
Exposure to 
tricyclic or tetracyclic antidepressants.  
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Table 2: Age-specific incidence rates of diabetes mellitus in people with (n=8,945) and without (n=2,727,565) schizophrenia 
Age 
group 
(years) 
People without schizophrenia People with schizophrenia  
 
mid-p 
b 
Person-
years 
(millions) 
Incident 
diabetes (n) 
Incidence 
rates
 a
  
95% CI  Person-
years 
 
Incident 
diabetes (n) 
Incidence 
rates 
a
 
95% CI 
0-9 23.66 3,449 0.15  0.14-0.15 29.12 0 0.00  - 0.99 
10-14 9.16 2,654 0.29 0.28-0.30 269.44 0 0.00  - 0.93 
15-19 7.34 2,462 0.33 0.32-0.35 4,824.17 13 2.69 1.56-4.64 <0.001 
20-24 5.15 1,776 0.35 0.33-0.36 16,263.53 59 3.63 2.81-4.68 <0.001 
25-29 2.98 2,100 0.70 0.67-0.75 16,941.88 75 4.43 3.53-5.55 <0.001 
30-36 1.24 1,474 1.18  1.12-1.25 8,987.59 56 6.23 4.80-8.10 <0.001 
0-36 49.53 13,915 0.28  0.28-0.29 47,315.73 203 4.29 3.74-4.92 <0.001 
 
a
 Incidence rates of diabetes mellitus per 1000 person-years; 
b 
Two-side exact significance comparing the incidence rates 
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Table 3: Endogenous risk for diabetes Mellitus in antipsychotic naive people with schizophrenia  
 Incidence 
rates 
a
 
 
 
95% CI 
a 
Adjusted 
hazard 
ratio 
 
 
95% CI  
Number 
Needed to 
Harm 
b
 
 
95% CI 
b
 
 
p-value 
Follow-up censored at first 
antipsychotic prescription 
c
 
 
People without schizophrenia 
(N=2,736,510) 
d
  
0.27  0.27-0.28 1.00  Reference   - 
People with schizophrenia (n=4,322)
 
1.84  1.05-5.15 2.92 
e
 1.66-5.15 
e
 1931 
e
 894-5614 
e
 <0.001 
People with schizophrenia (n=4,322)  1.84  1.05-5.15 3.07 
f
 1.71-5.41 
f
 1791
 f
 841-5219
 f
 <0.001 
No use of antipsychotics during the 
entire follow-up 
g
 
 
People without schizophrenia 
(n=2,673,114) 
0.27 0.27-0.28 1.00 Reference   - 
People with schizophrenia (n=1,154)
  
2.18 1.09-4.36 3.18 
e
 1.59-6.36 
e
 1700 
e
 692-6280 
e
 0.001 
People with schizophrenia (n=1,154)
 
 2.18 1.09-4.36 2.98
 f
 1.49-5.95
 f
 1872
 f
 749-7562
 f
 0.002 
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a 
Incidence rates of diabetes mellitus per 1000 person-years; 
b 
Number needed to harm in person years; 
c  
Data were censored at the 
earliest date among the following, date of diagnosis of diabetes, date of starting any antipsychotic medication, date of death, date of 
emigration from Denmark, and the end of follow-up on 1st January, 2013; 
d
 Assuming that the people with schizophrenia were at risk 
for diabetes after the diagnosis of schizophrenia, analyses were carried out with reference groups including data of people without 
schizophrenia, and of antipsychotic naive people with schizophrenia before the diagnosis of schizophrenia; 
e 
adjusted for the effects of 
gender, family history of diabetes, and urbanicity; 
f
 Adjusted for the effects of gender, family history of diabetes, urbanicity, exposure 
to valproate, and exposure to tricyclic or tetracyclic antidepressants; 
g 
Endogenous risk for diabetes in
 
people with schizophrenia, who 
remained antipsychotic naive until the end of follow-up, was evaluated with reference to people without schizophrenia, who have not 
been exposed to any antipsychotics. Mean duration of follow-up after the diagnosis of schizophrenia was 3.18 (SD=3.53) years in
 
people with schizophrenia, who remained antipsychotic naive until the end of follow-up.  
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Table 4: Antipsychotic-related incidence rates, adjusted hazard ratios and number needed to harm for Diabetes Mellitus in people with 
schizophrenia  
 Incidence 
rates 
a
  
 
95% CI 
a
 
Adjusted 
hazard 
ratio 
b
 
 
95% CI 
b
 
Number 
Needed to 
Harm 
c
 
 
95% CI 
c
 
 
p-value 
Risks with starting any 
antipsychotics 
 
Before starting any antipsychotic 
medication (n=4,322)
d 
1.69 0.94-3.05 1.00  Reference - - - 
After starting any antipsychotic 
medication (n=3,168) 
3.93  3.12-4.95 3.64 1.95-6.82 226 103-625 <0.001 
After first-line treatment with a first-
generation antipsychotic (n=450) 
3.92 2.23-6.91 3.06 1.32-7.05 289 99-1853 0.009 
After first-line treatment with a second-
generation antipsychotic (n=1,708) 
e 
 3.50
 
2.42-5.07  3.82 
 
1.81-8.09 211 85-733 <0.001 
After first-line treatment with a second-  3.36
 
2.48-4.57  3.44
 
1.73-6.83 244 103-813 <0.001 
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generation antipsychotic (n=2,311) 
f 
Risks with starting olanzapine  
Before starting olanzapine (n=7,652) 
g 
3.82  3.16-4.63 1.00  Reference - - - 
After starting olanzapine (n=2,115) 5.13 4.01-6.55 1.88 1.36-2.59 300 166-731 <0.001 
Risks with starting aripiprazole  
Before starting aripiprazole (n=8,358) 
h 
3.70 3.11-4.41 1.00  Reference - - - 
After starting aripiprazole (n=2,719) 5.32 4.13-6.87 2.35 1.70-3.26 202 121-389 <0.001 
Risks with starting clozapine  
Before starting clozapine (n=8,890) 
i 
3.78 3.24-4.41 1.00  Reference - - - 
After starting clozapine (n=862)  8.81  6.44-12.06 3.98 2.77-5.73 90 57-151 <0.001 
a 
Incidence rates of diabetes mellitus per 1000 person-years; 
b 
Adjusted hazard ratios that were estimated by cox proportional hazard 
regression models. These models included gender, family history of diabetes, and urbanicity as time-independent covariates, and 
calendar period, Defined Daily Doses (DDD) of antipsychotics, DDD of valproate, and DDD of tricyclic or tetracyclic antidepressants 
as time-dependent covariates; 
c 
Number needed to harm in person years; 
d 
People with schizophrenia, who were antipsychotic naïve at 
the time of diagnosis of schizophrenia; 
e 
Starting monotherapy with all second-generation antipsychotics except Olanzapine and 
Clozapine; 
f
 Starting monotherapy with all second-generation antipsychotics except Clozapine; 
g
 People with schizophrenia, who had 
received olanzapine before their diagnosis of schizophrenia, were excluded from this analysis: 
h
 People with schizophrenia, who had 
received aripiprazole before their diagnosis of schizophrenia, were excluded from this analysis; 
i
 People with schizophrenia, who had 
received clozapine before their diagnosis of schizophrenia, were excluded from this analysis. 
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